Literature DB >> 23744254

Neovascular glaucoma treatment with extraction of anterior chamber fibrovascular tissue.

Jeroni Nadal1, Elisa Carreras, Bachar Kudsieh, Maribel Canut.   

Abstract

The use of antibody to vascular endothelial growth factor to treat neovascular glaucoma yields good anatomic results in most cases. However, this type of glaucoma can cause angle closure with decompensation of intraocular pressure secondary to fibrovascular tissue contraction in the anterior chamber. Our surgical technique treats the cause by removing the anterior chamber fibrous complex after administration of antibody to vascular endothelial growth factor, thus restoring the chamber angle.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23744254     DOI: 10.1001/jamaophthalmol.2013.426

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN: 2168-6165            Impact factor:   7.389


  4 in total

Review 1.  Neovascular glaucoma: a review.

Authors:  Gustavo B Rodrigues; Ricardo Y Abe; Camila Zangalli; Savio L Sodre; Flavia A Donini; Danilo C Costa; Andre Leite; Joao P Felix; Marcelo Torigoe; Alberto Diniz-Filho; Homero Gusmão de Almeida
Journal:  Int J Retina Vitreous       Date:  2016-11-14

2.  Vascular Endothelial Growth Factor, Basic Fibroblast Growth Factor, and Pigment Epithelium-Derived Factor Expression in the Neovascular Iris in Retinal Diseases.

Authors:  Heng Miao; Xianru Hou; De-Kuang Hwang; Yong Tao
Journal:  J Ophthalmol       Date:  2018-04-11       Impact factor: 1.909

3.  Effectiveness of multiple therapeutic strategies in neovascular glaucoma patients: A PRISMA-compliant network meta-analysis.

Authors:  Zixian Dong; Jianyang Gong; Rongfeng Liao; Shaojun Xu
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

4.  Gonioscopy-assisted transluminal trabeculotomy in neovascular glaucoma: Salvaging the conventional outflow pathway.

Authors:  Jacob A Kanter; Pathik Amin; Rahul Komati; Anna G Mackin; David Dao; Lincoln T Shaw; Dimitra Skondra; Mary Qiu
Journal:  Am J Ophthalmol Case Rep       Date:  2022-07-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.